Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Overview | 9 | 1 |
| Therapeutics Development | 10 | 4 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Products under Development by Stage of Development | 10 | 1 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Products under Development by Therapy Area | 11 | 1 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Products under Development by Indication | 12 | 2 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Pipeline Products Glance | 14 | 2 |
| Late Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Products under Development by Companies | 16 | 3 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Products under Development by Universities/Institutes | 19 | 2 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Therapeutics Assessment | 21 | 5 |
| Assessment by Monotherapy/Combination Products | 21 | 1 |
| Assessment by Mechanism of Action | 22 | 2 |
| Assessment by Route of Administration | 24 | 1 |
| Assessment by Molecule Type | 25 | 1 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Companies Involved in Therapeutics Development | 26 | 11 |
| Addex Therapeutics Ltd | 26 | 1 |
| Bristol-Myers Squibb Company | 27 | 1 |
| Eisai Co., Ltd. | 28 | 1 |
| Eli Lilly and Company | 29 | 1 |
| Heptares Therapeutics Limited | 30 | 1 |
| Hua Medicine (Shanghai) Ltd. | 31 | 1 |
| Johnson &Johnson | 32 | 1 |
| Medgenics, Inc. | 33 | 1 |
| Merz Pharma GmbH &Co. KgaA | 34 | 1 |
| Sumitomo Dainippon Pharma Co., Ltd. | 35 | 1 |
| Toray Industries, Inc. | 36 | 1 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Drug Profiles | 37 | 30 |
| alloswitch-1 Drug Profile | 37 | 1 |
| BMS-952048 Drug Profile | 38 | 1 |
| BMS-955829 Drug Profile | 39 | 1 |
| dipraglurant ER Drug Profile | 40 | 1 |
| dipraglurant IR Drug Profile | 41 | 5 |
| Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome Drug Profile | 46 | 1 |
| DSR-98776 Drug Profile | 47 | 1 |
| fasoracetam Drug Profile | 48 | 2 |
| GET-73 Drug Profile | 50 | 1 |
| HTL-14242 Drug Profile | 51 | 1 |
| JNJ-46778212 Drug Profile | 52 | 1 |
| LSN-2463359 Drug Profile | 53 | 1 |
| LSN-2814617 Drug Profile | 54 | 1 |
| remeglurant Drug Profile | 55 | 1 |
| Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders Drug Profile | 56 | 1 |
| Small Molecule to Antagonize mGlu5 for Pain Drug Profile | 57 | 1 |
| Small Molecule to Antagonize mGluR5 for CNS Disorders Drug Profile | 58 | 1 |
| Small Molecules to Agonize mGluR5 for Schizophrenia Drug Profile | 59 | 1 |
| Small Molecules to Antagonize mGluR5 for Anxiety Drug Profile | 60 | 1 |
| Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders Drug Profile | 61 | 1 |
| Small Molecules to Antagonize mGluR5 for Dyskinesia Drug Profile | 62 | 1 |
| VU-0092273 Drug Profile | 63 | 1 |
| VU-0431316 Drug Profile | 64 | 1 |
| VU-0463841 Drug Profile | 65 | 1 |
| VU-0467558 Drug Profile | 66 | 1 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Dormant Projects | 67 | 4 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Discontinued Products | 71 | 2 |
| Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) Featured News &Press Releases | 73 | 14 |
| Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD | 73 | 1 |
| Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society | 73 | 1 |
| Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers | 74 | 2 |
| Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers | 76 | 1 |
| Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept | 77 | 1 |
| Jan 04, 2016: Addex Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson s Disease | 78 | 1 |
| Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial | 78 | 1 |
| Aug 14, 2015: Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson s Disease | 79 | 1 |
| Jul 22, 2015: Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation | 80 | 1 |
| Feb 23, 2015: Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation | 81 | 1 |
| Jan 19, 2015: Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia | 82 | 1 |
| Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 | 82 | 1 |
| May 01, 2013: Addex's Dipragluant Demonstrates Dose-dependent mGlu5 Receptor Occupancy In Non-human Primate PET Study | 83 | 2 |
| Apr 22, 2013: Addex Obtains European Composition Of Matter Patent Covering Dipraglurant And Other mGlu5 Negative Allosteric Modulators | 85 | 1 |
| Apr 18, 2013: Addex's Dipraglurant Normalizes Striatal Cholinergic Dysfunction In Validated Preclinical Model Of Primary Generalized Torsion Dystonia 1 | 85 | 2 |
| Appendix | 87 | 2 |
| Methodology | 87 | 1 |
| Coverage | 87 | 1 |
| Secondary Research | 87 | 1 |
| Primary Research | 87 | 1 |
| Expert Panel Validation | 87 | 1 |
| Contact Us | 87 | 1 |
| Disclaimer | 88 | 1 |
